Hua Medicine plans to join trendy Hong Kong IPO club, pitching an offering of up to $400M -- reports
A diabetes drug maker that has attracted investment from Arch Venture Partners, Venrock and WuXi AppTec is the latest Chinese company planning an IPO in Hong Kong.
Hua Medicine is expecting to raise $300 million to $400 million in the public offering, according to Bloomberg and Reuters, which both reported the news but cited different numbers. Reuters added that this will happen in the second half of 2018.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.